British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...

The FDA has accepted for review the sBLA to expand the indication of Arexvy (RSV vaccine, adjuvanted) to adults aged 18 to 49 years who are at increased risk.

London: GSK plc has announced that the US Food and Drug Administration (FDA) has accepted for review an application to extend ...

GSK plc GSK announced that the FDA has accepted its regulatory filing seeking to expand the use of its RSV vaccine, Arexvy, in adults under 50 who are at a higher risk of the disease. A final decision ...

The label expansion sought by GSK is a bid to compete with Pfizer and Moderna in the younger age groups of the RSV vaccine market. Pfizer’s Abrysvo and Moderna’s mRESVIA are both approved to prevent ...

GSK's Q3 2023 financials reveal strong performance fueled by Arexvy's sales, while caution is advised due to market movements. Read more here.

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified. See what to expect from GSK's Q3.

GSK GSK announced that the FDA has approved the expanded use of its respiratory syncytial virus (RSV) vaccine, Arexvy for adults aged 50-59 who are at increased risk of RSV disease. Arexvy is ...

GSK plc today announced that AREXVY is now available in the US at all major retail pharmacies. In June, the Advisory Committee on Immunization Practices recommended that persons 60 years of age ...

GSK shares positive data for AREXVY, its respiratory syncytial virus (RSV) older adult vaccine, indicating protection over two RSV seasons .

GSK Pfizer Arexvy RSV. As companies have flocked to compete in the new respiratory syncytial virus (RSV) vaccine market, GSK has had the best timing.